Law Firms Urge Telix Investors To Seek Lead Role by Jan. 9 in Securities Class Action

Overview

• Multiple plaintiff firms, including Rosen, Hagens Berman, Bragar Eagel & Squire, The Gross Law Firm, Glancy Prongay & Murray, and Levi & Korsinsky, issued fresh reminders about the deadline.
• The putative class covers purchasers of Telix securities from February 21, 2025 through August 28, 2025.
• Complaints allege Telix overstated progress on prostate cancer therapeutics and overstated the reliability and regulatory compliance of third‑party manufacturing and supply‑chain partners.
• Plaintiffs cite Telix’s July 22, 2025 disclosure of an SEC subpoena and an August 28, 2025 FDA Complete Response Letter for TLX250‑CDx that flagged CMC deficiencies and referenced Form 483 observations at two third‑party facilities.
• Filings note share declines after each disclosure, including a 10.4% drop on July 23 and a 16.1% drop on August 28, with notices emphasizing that no class has been certified and the litigation remains at an early stage.